Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse

黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生

基本信息

  • 批准号:
    9031727
  • 负责人:
  • 金额:
    $ 29.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-01 至 2019-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We propose to use a new experimental model of aflatoxin hepatocarcinogenesis in glutathione S- transferase A3 knockout mice (mGSTA3-/- or KO) to explore the role of oval cells (OCs) as precursors to hepatocellular carcinoma (HCC) not possible in other experimental models. HCC is a leading cause of cancer mortality worldwide, and dietary aflatoxin B1 (AFB1) exposure is a major risk factor. Adult mice are resistant to AFB1-induced liver injury because of high levels of constitutively expressed mGSTA3 that detoxifies activated AFB1. Humans do not have this efficient detoxification pathway, so that the mGSTA3-/- mice may be considered humanized in regard to AFB1 metabolism and sensitivity. Both male and female mGSTA3 KO mice respond to low doses of AFB1 with liver injury and massive OC proliferation. In Specific Aim 1, we will define the effects of loss of the mGSTA3 on AFB1-induced toxicity, by measuring the steps of AFB1 metabolism, the levels of AFB1-DNA adducts and extent of oxidative damage in liver tissues. This will provide a mechanistic insight into AFB1 carcinogenesis and should explain the differences in susceptibility to acute AFB1 toxicity between male and female mGSTA3-/- mice that we have observed. In Specific Aim 2, four regimens of AFB1 exposure in mGSTA3-/- mice will be used to determine one, or several, that would best serve to study the AFB1-induced injury and development of HCCs. The models will be designed to target oval cells, mimic initiation + promotion protocols and include cross-breeding with chronic hepatitis-prone transgenic mice. In Specific Aim 3, the fate of oval cells after proliferation will be specifically addressed. Following AFB1- induced liver injury, their origin, expansion and differentiation into either mature cells or to liver cancer, will be studied under different AFB1 exposure protocols. The oval cell response in mGSTA3-/- mice is much greater, different in growth pattern and more relevant to human health than other mouse models reported. These studies will provide new insights into aflatoxin B1-associated carcinogenesis, identify the sequence of events that leads to tumor development, determine the role of oval cells as cancer stem cells and provide mechanisms that can be targeted to prevent AFB1-induced liver toxicity and cancer in the future.
描述(由申请人提供):我们建议在谷胱甘肽S-转移酶A3敲除小鼠(mGSTA 3-/-或KO)中使用黄曲霉毒素肝癌发生的新实验模型,以探索卵圆细胞(OC)作为肝细胞癌(HCC)前体的作用,这在其他实验模型中是不可能的。HCC是全球癌症死亡率的主要原因,而膳食黄曲霉毒素B1(AFB 1)暴露是一个主要的风险因素。成年小鼠对AFB 1诱导的肝损伤具有抵抗力,因为高水平的组成型表达mGSTA 3可以解毒激活的AFB 1。人类没有这种有效的解毒途径,因此mGSTA 3-/-小鼠在AFB 1代谢和敏感性方面可能被认为是人源化的。雄性和雌性mGSTA 3 KO小鼠对低剂量的AFB 1都有反应,伴有肝损伤和大量OC增殖。在具体目标1中,我们将通过测量AFB 1代谢的步骤、AFB 1-DNA加合物的水平和肝组织中氧化损伤的程度来确定mGSTA 3缺失对AFB 1诱导的毒性的影响。这将为AFB 1致癌机制提供一个机制性的见解,并应解释我们观察到的雄性和雌性mGSTA 3-/-小鼠对急性AFB 1毒性敏感性的差异。在特定目标2中,将使用mGSTA 3-/-小鼠中的四种AFB 1暴露方案来确定一种或几种最适合研究AFB 1诱导的肝细胞癌损伤和发展的方案。该模型将被设计为靶向卵圆细胞,模拟启动+促进方案,并包括与慢性肝炎易感转基因小鼠的杂交育种。在具体目标3中,将专门讨论增殖后卵圆细胞的命运。在AFB 1诱导的肝损伤后,将在不同的AFB 1暴露方案下研究它们的起源、扩增和分化为成熟细胞或肝癌。mGSTA 3-/-小鼠的卵圆细胞反应更大,生长模式不同,与其他小鼠模型报告的人类健康更相关。这些研究将为黄曲霉毒素B1相关的致癌作用提供新的见解,确定导致肿瘤发展的事件序列,确定卵圆细胞作为癌症干细胞的作用,并提供可靶向预防AFB 1诱导的肝毒性和癌症的机制。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells.
  • DOI:
    10.18632/oncotarget.10395
  • 发表时间:
    2016-08-02
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Muralidharan-Chari V;Kohan HG;Asimakopoulos AG;Sudha T;Sell S;Kannan K;Boroujerdi M;Davis PJ;Mousa SA
  • 通讯作者:
    Mousa SA
Immunopathology of Experimental Models of Syphilis, Influenza, and Asthma.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEWART SELL其他文献

STEWART SELL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEWART SELL', 18)}}的其他基金

Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生
  • 批准号:
    8827703
  • 财政年份:
    2012
  • 资助金额:
    $ 29.27万
  • 项目类别:
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生
  • 批准号:
    8629710
  • 财政年份:
    2012
  • 资助金额:
    $ 29.27万
  • 项目类别:
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生
  • 批准号:
    8293559
  • 财政年份:
    2012
  • 资助金额:
    $ 29.27万
  • 项目类别:
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
黄曲霉毒素 B1 在 mGSTA3-/- 小鼠中的肝癌发生
  • 批准号:
    8464677
  • 财政年份:
    2012
  • 资助金额:
    $ 29.27万
  • 项目类别:
STEM CELLS AND AGEING
干细胞与衰老
  • 批准号:
    7121494
  • 财政年份:
    2005
  • 资助金额:
    $ 29.27万
  • 项目类别:
STEM CELLS AND AGING
干细胞与衰老
  • 批准号:
    7233574
  • 财政年份:
    2005
  • 资助金额:
    $ 29.27万
  • 项目类别:
STEM CELLS AND HEPATOCARCINOGENESIS
干细胞与肝癌发生
  • 批准号:
    7436364
  • 财政年份:
    2005
  • 资助金额:
    $ 29.27万
  • 项目类别:
STEM CELLS AND HEPATOCARCINOGENESIS
干细胞与肝癌发生
  • 批准号:
    7235325
  • 财政年份:
    2005
  • 资助金额:
    $ 29.27万
  • 项目类别:
STEM CELLS AND HEPATOCARCINOGENESIS
干细胞与肝癌发生
  • 批准号:
    7625965
  • 财政年份:
    2005
  • 资助金额:
    $ 29.27万
  • 项目类别:
STEM CELLS AND HEPATOCARCINOGENESIS
干细胞与肝癌发生
  • 批准号:
    7103671
  • 财政年份:
    2005
  • 资助金额:
    $ 29.27万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了